Literature DB >> 18852005

Deceptive imprinting and immune refocusing in vaccine design.

Gregory J Tobin1, Jessie D Trujillo, Ruth V Bushnell, George Lin, A Ray Chaudhuri, Jinxue Long, Jose Barrera, Lindomar Pena, Marvin J Grubman, Peter L Nara.   

Abstract

A large number of the world's most widespread and problematic pathogens evade host immune responses by inducing strain-specific immunity to immunodominant epitopes with high mutation rates capable of altering antigenic profiles. The immune system appears to be decoyed into reacting to these immunodominant epitopes that offer little cross protection between serotypes or subtypes. For example, during HIV-1 infection, the immune system reacts strongly to the V1, V2, and/or V3 loops of the surface envelope glycoprotein but not to epitopes that afford broad protection against strain variants. Similarly, the host mounts strain-specific immunity to immunodominant epitopes of the influenza hemagglutinin (HA) protein. A large number of pathogens appear to exploit this weakness in the host immune system by focusing antigenic attention upon highly variable epitopes while avoiding surveillance toward more highly conserved receptor binding sites or other essential functional domains. Because the propensity of the immune system to react against immunodominant strain-specific epitopes appears to be genetically hard-wired, the phenomenon has been termed "deceptive imprinting." In this review, the authors describe observations related to deceptive imprinting in multiple systems and propose strategies for overcoming this phenomenon in the design of vaccines capable of inducing protection against highly variable pathogens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852005     DOI: 10.1016/j.vaccine.2008.09.080

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  51 in total

1.  An engineered mutant of HIV-1 gp120 formulated with adjuvant Quil A promotes elicitation of antibody responses overlapping the CD4-binding site.

Authors:  Fatima K Ahmed; Brenda E Clark; Dennis R Burton; Ralph Pantophlet
Journal:  Vaccine       Date:  2011-12-04       Impact factor: 3.641

2.  Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.

Authors:  Natalie A Parlane; Katrin Grage; Jun Mifune; Randall J Basaraba; D Neil Wedlock; Bernd H A Rehm; Bryce M Buddle
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

3.  Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein.

Authors:  Ruth V Bushnell; John K Tobin; Jinxue Long; Stacey Schultz-Cherry; A Ray Chaudhuri; Peter L Nara; Gregory J Tobin
Journal:  Virol J       Date:  2010-08-24       Impact factor: 4.099

4.  Developing strategies to enhance and focus humoral immune responses using filamentous phage as a model antigen.

Authors:  Kevin A Henry; Armstrong Murira; Nienke E van Houten; Jamie K Scott
Journal:  Bioeng Bugs       Date:  2011-09-01

5.  Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Authors:  James M Binley; Yih-En Andrew Ban; Emma T Crooks; Dirk Eggink; Keiko Osawa; William R Schief; Rogier W Sanders
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

Review 6.  Vaccines for the common cold.

Authors:  Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata
Journal:  Cochrane Database Syst Rev       Date:  2017-05-18

7.  The state of norovirus vaccines.

Authors:  Kari Debbink; Lisa C Lindesmith; Ralph S Baric
Journal:  Clin Infect Dis       Date:  2014-02-27       Impact factor: 9.079

Review 8.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

9.  Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic.

Authors:  Rui Xu; Ryan McBride; James C Paulson; Christopher F Basler; Ian A Wilson
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

Review 10.  Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Authors:  Francis B Ntumngia; Christopher L King; John H Adams
Journal:  Int J Parasitol       Date:  2012-10-12       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.